

Life is calling... *Take control*



BRUKINSA is a type of targeted oral therapy called a Bruton's tyrosine kinase (BTK) inhibitor. BRUKINSA is a prescription medicine used to treat adults with:

- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Waldenström's macroglobulinemia (WM).
- Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
- Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
- Follicular lymphoma (FL), in combination with the medicine obinutuzumab, when the disease has come back or did not respond to treatment and who have received at least two prior treatments.

BRUKINSA was approved for MCL, MZL, and FL based on response rate. There are ongoing evaluations to confirm clinical benefit for these uses.

It is not known if BRUKINSA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

BRUKINSA may cause serious side effects, including:


Bleeding problems (hemorrhage). Bleeding problems are common with BRUKINSA, and can be serious and may lead to death. Your risk of bleeding may increase if you are also taking a blood thinner medicine.

Please see additional Important Safety Information throughout and accompanying full Patient Information.

What are B-cell lymphomas?

The role of B cells

- B cells (also known as B lymphocytes) are a type of white blood cell found in your blood and bone marrow
- When B cells develop normally, they help protect the body from infection and disease
- B-cell lymphomas, such as CLL/SLL, WM, MCL, MZL, and FL, are caused by the growth and spread of abnormal, or cancerous, B cells



The role of BTK

- BTK is a protein that sends non-stop signals to cancerous B cells to grow and spread
- Blocking BTK can help stop this signaling

Shutting down, or inhibiting, BTK may help stop the signaling in cancerous B cells.

What is BRUKINSA?

BRUKINSA is a BTK inhibitor designed to treat CLL/SLL, WM, MCL, MZL, and FL

- A BTK inhibitor is a targeted treatment that works to shut down (or inhibit) BTK

BRUKINSA was designed to shut down BTK signaling and keep it shut down around the clock.

- BRUKINSA has been shown to block 100% of BTK in blood cells and 94% to 100% of BTK in lymph nodes when taken at the recommended total daily dose of 320 mg. The significance of blocking up to 100% of BTK on treatment responses has not been established

IMPORTANT SAFETY INFORMATION

BRUKINSA may cause serious side effects, including: Bleeding problems (hemorrhage) (continued). Tell your healthcare provider if you have any signs or symptoms of bleeding, including: blood in your stools or black stools (looks like tar), pink or brown urine, unexpected bleeding, or bleeding that is severe or you cannot control, vomit blood or vomit that looks like coffee grounds, cough up blood or blood clots, increased bruising, dizziness, weakness, confusion, change in speech, or headache that lasts a long time.

Please see additional Important Safety Information throughout and accompanying full [Patient Information](#).





How was BRUKINSA studied?

Over **1,700 patients** with CLL/SLL, WM, MCL, MZL, or FL were treated with BRUKINSA in clinical trials

- Some trials included patients who had not yet received treatment for their disease. Other trials included patients who had received prior treatment
- In some clinical trials, BRUKINSA was directly compared to other approved treatment options for the same disease
- In FL, BRUKINSA is taken with another medicine called obinutuzumab. This combination was studied in a clinical trial that included patients who had received prior treatments



For information about how BRUKINSA was shown to be effective against your disease, talk to your doctor or visit [BRUKINSA.com](https://www.brukinsa.com).

IMPORTANT SAFETY INFORMATION

BRUKINSA may cause serious side effects, including:

Infections that can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, or flu-like symptoms.

Heart rhythm problems (atrial fibrillation, atrial flutter, and ventricular arrhythmias) that can be serious and may lead to death. Tell your healthcare provider if you have any of the following signs or symptoms: your heartbeat is fast or irregular, feel lightheaded or dizzy, pass out (faint), shortness of breath, or chest discomfort.

What are the most common side effects of BRUKINSA?

People taking BRUKINSA may experience side effects

The most common ones include:

- Decreased white blood cell count
- Upper respiratory tract infection
- Decreased platelet count
- Muscle, bone, or joint pain
- Bleeding

These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects, particularly if you have any new or worsening ones. You may report side effects to the FDA at 1-800-FDA-1088.

Your doctor can help manage side effects to help you feel better and stay on treatment.

IMPORTANT SAFETY INFORMATION

BRUKINSA may cause serious side effects, including:

Decrease in blood cell counts (white blood cells, platelets, and red blood cells). Your healthcare provider should do blood tests during treatment with BRUKINSA to check your blood counts.

Please see additional Important Safety Information throughout and accompanying full [Patient Information](#).



How is BRUKINSA taken?

Your doctor can prescribe BRUKINSA either once or twice daily—making it the only BTK inhibitor that offers the choice of **2 dosing schedules**

- BRUKINSA is an oral prescription medicine with a recommended dose of 320 mg daily taken as four 80-mg capsules with or without food

ONCE A DAY

for convenience



4 capsules
taken once daily

OR

TWICE A DAY

to match the schedule of other
medicines you may take



2 capsules in the morning,
2 capsules later in the day

Talk with your doctor about which dosing schedule may be right for you.

Is there other important dosing information?

Take BRUKINSA exactly as prescribed

- Do not switch your dosing schedule without discussing with your doctor first
- BRUKINSA capsules can be taken with or without food. They should be taken whole with water—do not open, break, or chew them

If you miss a dose of BRUKINSA, take it as soon as you remember

- Try to take it on the same day. Return to your normal schedule the next day

Tell your doctor about all the medications you are currently taking, as well as certain supplements and foods

This includes prescription and over-the-counter medicines, vitamins, herbal supplements, and certain citrus fruits, such as:

- Echinacea
- Ginseng
- Goldenseal
- St. John's wort
- Grapefruit juice
- Seville oranges

You will take BRUKINSA for as long as your doctor thinks it is helping you, or for as long as side effects are manageable

- Your dose and schedule may be changed or interrupted by your doctor to meet your individual treatment needs, including managing side effects

IMPORTANT SAFETY INFORMATION

BRUKINSA may cause serious side effects, including:

Second primary cancers. New cancers have happened in people during treatment with BRUKINSA, including cancers of the skin or other organs. Your healthcare provider will check you for other cancers during treatment with BRUKINSA. Use sun protection when you are outside in sunlight.

Please see additional Important Safety Information throughout and accompanying full [Patient Information](#).



myBeiGene®

Patient Support Program

We want you to focus on your treatment and living your life.

To meet your needs, myBeiGene pairs you with a dedicated Oncology Nurse Advocate who will personalize support for you and your caregiver throughout treatment with BRUKINSA.

Program services include:



Simplifying access to BRUKINSA through financial assistance



Educating you and your caregivers about your treatment and disease



Connecting you and your caregivers to services that deliver day-to-day living support



*For any questions, or to help you get started,
call **1-833-BEIGENE (1-833-234-4363)**, M-F 8 AM-8 PM ET,
or visit myBeiGene.com.*

BRUKINSA, BeiGene, and myBeiGene are registered trademarks owned by BeiGene, Ltd. or its affiliates.

myBeiGene® is not insurance and does not guarantee product coverage or reimbursement.

© BeiGene, Ltd. 2024 All Rights Reserved.
0819-BRU-PRC-035-r5 3/2024

